

a default judgment—or any judgment not defended by the NVOCC or its surety—to determine whether a claim is within the scope of the bond.

Interested persons may inspect and obtain a copy of the petition at the Office of the Secretary, Room 1046, Federal Maritime Commission, 800 North Capital Street, NW., Washington, DC 20573-0001. Interested persons may reply to the petition by submitting an original and 15 copies of the reply to the Secretary, at the above address, on or before August 25, 1997. A copy of the reply also shall be served on petitioner's attorney, Henry P. Gonzalez, Esq., Carlos Rodriguez & Associates, 1710 Rhode Island Ave., NW., Tenth Floor, Washington, DC 20036, and on counsel for Wilhelmsen Lines A/S, Alan Nakazawa, Esq., Williams Wooley Cogswell Nakazawa & Russell, 111 West Ocean Boulevard, Suite 2000, Long Beach, California 90802-4614. Replies shall contain the complete factual and legal presentation of the replying party as to the desired resolution of the petition (See 46 CFR 502.68(d)).

Joseph C. Polking,

Secretary.

[FR Doc. 97-20112 Filed 7-30-97; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

Editorial Note.—FR document 97-19206 was originally published beginning on page 39242, in the issue of Tuesday, July 22, 1997, it was inadvertently published with incorrect text. The correct text appears below.

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than August 6, 1997.

A. Federal Reserve Bank of San Francisco (Pat Marshall, Manager of Analytical Support, Consumer

Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Richard A. Lagomarsino, and Robert J. Lagomarsino*, both of Ventura, California, and Catherine S. Wood, Carpinteria, California; acting in concert to acquire an additional .05 percent, for a total of 19.06 percent, of the voting shares of Americorp, Ventura, California, and thereby indirectly acquire American Commercial Bank, Ventura, California.

Board of Governors of the Federal Reserve System, July 17, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-19206 Filed 7-30-97; 8:45 am]

BILLING CODE 1505-01-F

FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act Meeting

TIME AND DATE: 10:00 a.m. (EDT) August 11, 1997.

PLACE: 4th Floor, Conference Room 4506, 1250 H Street, NW., Washington DC.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Approval of the minutes of the July 14, 1997, Board member meeting.
2. Thrift Savings Plan activity report by the Executive Director.
3. Review of investment policy.
4. Review of Arthur Andersen semiannual financial review.
5. Review of KPMG Peat Marwick audit report: "Pension and Welfare Benefits Administration Review of the Thrift Savings Plan Withdrawal and Inactive Accounts Operations at the United States Department of Agriculture, National Finance Center."

CONTACT PERSON FOR MORE INFORMATION: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942-1640.

Roger W. Mehle,

Executive Director, Federal Retirement Thrift Investment Board.

[FR Doc. 97-20354 Filed 7-29-97; 12:20 pm]

BILLING CODE 6760-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 761]

Replication and Dissemination of Effective Breast and Cervical Cancer Health Education Interventions

Amendment

A notice announcing the availability of fiscal year (FY) 1997 funds for cooperative agreements for the Replication and Dissemination of Effective Breast and Cervical Cancer Health Education Interventions was published in the **Federal Register** on July 8, 1997, (62 FR 36522). The notice is amended as follows:

On page 36523, first column, under the heading "Availability of Funds," the first two sentences are changed to read: "Approximately \$4.5 million will be available in FY 1997 to fund approximately 10 awards. It is expected that the average award will be approximately \$350,000, ranging from \$350,000 to \$500,000."

On page 36528, first column, under the heading "Application Submission and Deadline," the date on lines nine and ten is changed to read "on or before August 20, 1997."

All other information and requirements of the July 8, 1997, **Federal Register** notice remain the same.

Dated: July 25, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-20137 Filed 7-30-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Announcement Number 789]

Research and Demonstration Programs in Surveillance, Prevention, and Control of Healthcare-Associated Infections and Antimicrobial Resistant Infections

Amendment

A notice announcing the availability of fiscal year (FY) 1997 funds for cooperative agreements for Research and Demonstration Programs in Surveillance, Prevention, and Control of Healthcare-Associated Infections and

Antimicrobial Resistant Infections was published in the **Federal Register** on July 8, 1997, (62 FR 36541). The notice is amended as follows:

On page 36543, under the heading "Specific Instructions," second column, 4. Objectives and Technical Approach, lines three and four have been changed and should read: "Recipient Activities (A.1.a., A.1.b., A.2., A.3., and A.4.). . . ."

On page 36544, second column, third paragraph, c., line six should read "Activities A.4.). . . ."

All other information and requirements of the July 8, 1997, **Federal Register** notice remain the same.

Dated: July 25, 1997.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-20136 Filed 7-30-97; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Blood Products Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations to fill upcoming vacancies on the Blood Products Advisory Committee.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or disabled candidates.

DATES: Nominations should be received on or before August 15, 1997.

ADDRESSES: All nominations for membership should be sent to the appropriate contact person (address below).

FOR FURTHER INFORMATION CONTACT:

All nominations and curricula vitae except for consumer representatives should be submitted in writing to Linda A. Smallwood, Office of Blood Research and Review (HFM-350), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD

20852-1448, 301-827-3514.

All nominations and curricula vitae for consumer representatives should be submitted in writing to Annette J. Funn, Office of Consumer Affairs (HFE-88), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5006.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations to fill upcoming vacancies on the Blood Products Advisory Committee. The function of the committee is to review and evaluate available data concerning the safety, effectiveness, appropriate use of blood products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which FDA has regulatory responsibility. Persons nominated for membership should be among authorities knowledgeable in the fields of clinical and administrative medicine, infectious disease, hematology, immunology, transfusion medicine, surgery, internal medicine, biochemistry, biostatistics, epidemiology, biological and physical sciences, biotechnology, computer technology, sociology/ethics, and other related professions. The membership will also include representatives of consumer organizations, product recipients, and health care providers. The committee will function at times as a medical device panel under the Federal Food, Drug, and Cosmetic Act Medical Device Amendments of 1976.

Nonvoting Consumer and Industry Representation

Section 520(f)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(f)(3)), as amended by the Medical Device Amendments of 1976, provides that each medical device panel include as members one nonvoting representative of consumer interests and one nonvoting representative of interests of the manufacturing industry.

Nomination Procedures

Interested persons may nominate one or more qualified persons for membership on the committee. Self nominations are also accepted. A current curriculum vitae of each nominee should accompany the letter of nomination and include the following information: Full name and title, business address and phone number, home address and phone number, date and place of birth. Nominations shall state that the nominee is willing to serve as a member of the committee and appears to have no conflict of interest that would preclude advisory committee membership. The Commissioner of

Food and Drugs will ask the potential candidates to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest. The term of office may not exceed 4 years, depending on the appointment date.

The nomination procedures for the nonvoting consumer representative and industry representative are the same as stated previously with the following exceptions:

Consumer Representatives

To be eligible for selection, the applicant's experience and/or education will be evaluated against Federal civil service criteria for the position to which the person will be appointed. The term of office is up to 4 years.

Industry Representatives

Any organization representing industry interests wishing to participate in the selection of representatives may nominate one or more qualified persons to represent industry interests. Persons who nominate themselves as industry representatives will not participate in the selection process. It is, therefore, recommended that all nominations be made by someone with an organization, trade association, or firm who is willing to participate in the selection process. Nominees shall be full-time employees of firms that manufacture products that would come before the committee, or consulting firms that represent manufacturers. The term of office is up to 4 years.

Selection Procedures

Consumer Representatives

Selection of members representing consumers interests is conducted through procedures which include use of a consortium of consumer organizations which has the responsibility for recommending candidates for the agency's selection. Candidates should possess appropriate qualifications to understand and contribute to the committee's work.

Industry Representatives

Regarding nominations for members representing the interests of industry, a letter will be sent to each person that has made a nomination, and to those organizations indicating an interest in participating in the selection process, together with a complete list of all such organizations and the nominees. This letter will state that it is the responsibility of each nominator or